Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone (2016)
- Authors:
- Autor USP: RONSEIN, GRAZIELLA ELIZA - IQ
- Unidade: IQ
- DOI: 10.1074/mcp.M115.054528
- Subjects: APOLIPOPROTEÍNAS; LIPOPROTEÍNAS HDL; DIABETES MELLITUS
- Language: Inglês
- Imprenta:
- Source:
- Título: Molecular e Cellular Proteomics
- ISSN: 1535-9476
- Volume/Número/Paginação/Ano: v. 15, n. 3, p. 1083-1093, 2016
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
RONSEIN, Graziella Eliza et al. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone. Molecular e Cellular Proteomics, v. 15, n. 3, p. 1083-1093, 2016Tradução . . Disponível em: https://doi.org/10.1074/mcp.M115.054528. Acesso em: 13 fev. 2026. -
APA
Ronsein, G. E., Reyes Soffer, G., He, Y., Oda, M., Ginsberg, H., & Heinecke, J. W. (2016). Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone. Molecular e Cellular Proteomics, 15( 3), 1083-1093. doi:10.1074/mcp.M115.054528 -
NLM
Ronsein GE, Reyes Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone [Internet]. Molecular e Cellular Proteomics. 2016 ; 15( 3): 1083-1093.[citado 2026 fev. 13 ] Available from: https://doi.org/10.1074/mcp.M115.054528 -
Vancouver
Ronsein GE, Reyes Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone [Internet]. Molecular e Cellular Proteomics. 2016 ; 15( 3): 1083-1093.[citado 2026 fev. 13 ] Available from: https://doi.org/10.1074/mcp.M115.054528 - Investigating the relationship between High-Density Lipoprotein (HDL) and endothelial cells
- HDL proteome: from its characterization to quantitative measurements in particle subspecies and functional associations
- Cholesterol efflux capacity and subclasses of HDL particles in healthy women transitioning through menopause
- Plasminogen promotes cholesterol efflux by the ABCA1 pathway
- Time to ditch HOL-C as a measure of PINION HOL function?
- Inflammation, remodeling, and other factors affecting HDL cholesterol efflux
- Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects
- Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathway
- Oxidação do triptofano pelo oxigenio molecular no estado singlete [´OIND.2´(´ANTPOT.1´DELTA IND.g´)]: estudos mecanisticos envolvendo marcação isotopica, espectrometria de massa e quimiluminescencia
- Patients with coronary endothelial dysfunction have impaired cholesterol efflux capacity and reduced HDL particle concentration
Informações sobre o DOI: 10.1074/mcp.M115.054528 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
